In our previous work, we demonstrated that combined shRNA-mediated silencing of β-catenin and KRAS in CRC cells led to massive induction of apoptosis in vitro and suppression of tumor growth in vivo, while individually targeting either of the two pathways showed modest effects [19]. The gene discussed is KRAS; the disease is neoplasm.